Filing Details
- Accession Number:
- 0000950170-23-068373
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-05 18:59:30
- Reporting Period:
- 2023-12-01
- Accepted Time:
- 2023-12-05 18:59:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817838 | Douglas Joseph Lyon | C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025 | Chief Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-12-01 | 2,568 | $11.35 | 8,422 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-01 | 2,568 | $26.00 | 5,854 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-12-04 | 2,432 | $11.35 | 8,286 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-04 | 2,432 | $26.00 | 5,854 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-12-01 | 460 | $25.97 | 6,314 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2023-12-01 | 460 | $0.00 | 6,774 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2023-12-01 | 5,000 | $0.00 | 5,000 | $11.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 44,167 | 2029-02-08 | No | 4 | M | Direct |
Footnotes
- Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
- The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023.
- In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- Fully exercisable.
Billionaire Hedge Funds
